Cargando…
Cutaneous Lymphoma and Antibody-Directed Therapies
The introduction of monoclonal antibodies such as rituximab to the treatment of cancer has greatly advanced the treatment scenario in onco-hematology. However, the response to these agents may be limited by insufficient efficacy or resistance. Antibody–drug conjugates are an attractive strategy to d...
Autores principales: | Sernicola, Alvise, Ciolfi, Christian, Miceli, Paola, Alaibac, Mauro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045448/ https://www.ncbi.nlm.nih.gov/pubmed/36975368 http://dx.doi.org/10.3390/antib12010021 |
Ejemplares similares
-
Role of Human Leukocyte Antigen Class II in Antibody-Mediated Skin Disorders
por: Sernicola, Alvise, et al.
Publicado: (2023) -
Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability
por: Ciolfi, Christian, et al.
Publicado: (2022) -
Primary Cutaneous B-Cell Lymphomas in Patients With Impaired Immunity
por: Russo, Irene, et al.
Publicado: (2020) -
Editorial: Cutaneous manifestations of systemic disease
por: Sernicola, Alvise, et al.
Publicado: (2023) -
Neoplastic and Autoimmune Comorbidities in Patients with Primary Cutaneous B-Cell Lymphoma
por: Mazzetto, Roberto, et al.
Publicado: (2023)